ProstaLund (PLUN) Q1 2025 earnings summary

Executive summary

• Net sales for Q1 2025 increased 7.1% year-over-year to SEK 3.7 million, with improved gross margin at 74.0% compared to 69.7% last year.

• Operating loss widened to SEK -5.0 million from SEK -4.7 million year-over-year; profit after tax was SEK -5.0 million.

• Cash flow from operating activities improved to SEK -4.2 million from SEK -6.6 million year-over-year.

• Launch of CoreTherm® Eagle began, with first patients treated and international expansion underway.

• Strategic review initiated due to weakened liquidity; SEK 2.5 million loan raised and SEK 5.5 million directed share issue planned.

Financial highlights

• Net sales: SEK 3.7 million (Q1 2025) vs SEK 3.5 million (Q1 2024).

• Gross margin: 74.0% (Q1 2025) vs 69.7% (Q1 2024).

• Operating loss (EBIT): SEK -5.0 million (Q1 2025) vs SEK -4.7 million (Q1 2024).

• Earnings per share: SEK -1.39 (Q1 2025) vs SEK -2.49 (Q1 2024).

• Cash and cash equivalents at period end: SEK 2.4 million (Q1 2025) vs SEK 6.9 million (Q1 2024).

Outlook and guidance

• Focus on strengthening sales efforts and international expansion, particularly with CoreTherm® Eagle.

• Management highlights ongoing interest and new discussions with international customers and distributors.

• Uncertainties remain regarding future cash flows and financing; going concern assumption maintained.